Supplier
Pediatrics and Family Care LLC
Pediatrics and Family Care LLC was paid $2.82M by Medicaid between Jan 2019 and Oct 2024, across 69 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider infoPEDIATRICS AND FAMILY CARE LLC
ORLANDO, FL 32812
ORLANDO, FL 32812
33aNPI1487162632assigned 01/22/2018
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$2.82M
24GClaims81,473
24DCodes billed69
24AFirst – last monthJan 2019 – Oct 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Florida
Rank by total paid#50 of 827
Median peer was paid$730.02
This provider vs. median3,867×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 5,939 | $153K | |
| 2020 | 4,917 | $162K | |
| 2021 | 11,181 | $412K | |
| 2022 | 17,572 | $655K | |
| 2023 | 24,338 | $879K | |
| 2024incomplete | 17,526 | $562K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 10,039 | 8,328 | $802K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 3,724 | 3,156 | $429K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 11% | 2,647 | 2,505 | $316K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 8.7% | 2,369 | 2,096 | $247K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 6.4% | 5,947 | 5,419 | $180K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.6% | 1,395 | 1,360 | $158K |
| 90461 | 3.2% | 3,227 | 2,993 | $91K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.0% | 1,587 | 1,523 | $85K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.8% | 1,720 | 1,609 | $78K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.2% | 542 | 532 | $63K |
| 97803 | 2.1% | 3,118 | 2,899 | $58K | |
| 99188 | 1.3% | 3,241 | 2,981 | $37K |
57 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 2,671 | $33K |
| 90670 | 1.1% | 1,152 | $31K | |
| 99383 | 1.0% | 233 | $29K | |
| 99382 | <1% | 172 | $22K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 169 | $18K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 4,610 | $18K |
| 90710 | <1% | 705 | $16K | |
| 99381 | <1% | 145 | $14K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 1,031 | $12K |
| 99384 | <1% | 84 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 767 | $10K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 213 | $8K |
| 92552 | <1% | 1,140 | $6K | |
| 83655 | <1% | 716 | $6K | |
| 96160 | <1% | 3,892 | $5K | |
| 99173 | <1% | 3,682 | $4K | |
| 85018 | <1% | 3,496 | $4K | |
| 96127 | <1% | 2,420 | $4K | |
| 97802 | <1% | 176 | $3K | |
| 92551 | <1% | 2,552 | $2K | |
| 90686 | <1% | 1,644 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 236 | $2K |
| 81002 | <1% | 1,069 | $2K | |
| 90680 | <1% | 732 | $2K | |
| 90633 | <1% | 1,125 | $2K | |
| 90651 | <1% | 178 | $1K | |
| 96161 | <1% | 990 | $1K | |
| 90671 | <1% | 186 | $1K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 59 | $1K |
| 90677 | <1% | 224 | $953.35 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 145 | $882.31 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 57 | $858.08 |
| 90698 | <1% | 268 | $763.08 | |
| 0071A | <1% | 15 | $553.37 | |
| 0072A | <1% | 13 | $520.00 | |
| 94664 | <1% | 61 | $437.63 | |
| 94667 | <1% | 150 | $370.01 | |
| 90648 | <1% | 1,037 | $361.31 | |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 1,582 | $346.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 16 | $336.14 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 108 | $276.12 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 93 | $249.89 |
| 90734 | <1% | 187 | $187.89 | |
| 90696 | <1% | 97 | $172.72 | |
| 90620 | <1% | 26 | $150.94 | |
| 90723 | <1% | 546 | $97.97 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 63 | $95.53 |
| 90700 | <1% | 189 | $58.39 | |
| 90681 | <1% | 12 | $24.01 | |
| 36416 | <1% | 88 | $5.28 | |
| A7005 | Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable | 0% | 31 | $0.00 |
| 94060 | 0% | 63 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 510 | $0.00 |
| 90656 | 0% | 12 | $0.00 | |
| 91307 | 0% | 41 | $0.00 | |
| 90744 | 0% | 15 | $0.00 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUMGARNER, MARILIZ (OWNER)